SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASESettlement Agreement and Mutual General Release • March 17th, 2006 • Praecis Pharmaceuticals Inc • Pharmaceutical preparations
This Settlement Agreement and Mutual General Release (hereinafter referred to as this “Release Agreement”) is entered into as of the 19th day of October, 2005 by and between PRAECIS PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware having its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451, USA (hereinafter referred to as “Praecis”) and SCHERING AG, a corporation organized and existing under the laws of Germany having its principal place of business at 13442 Berlin, Germany (hereinafter referred to as “Schering”), who may be referred to individually herein as a “Party” and collectively as the “Parties”
LETTER AGREEMENTLetter Agreement • March 17th, 2006 • Praecis Pharmaceuticals Inc • Pharmaceutical preparations • New York
Whereas, on June 21, 2000, UCB and Amgen Inc. (“AMGEN”) executed a contract for the development and supply of bulk API for a compound identified as Abarelix (the “Original Agreement”), as assigned by AMGEN to Praecis effective on December 17, 2001 and as amended by Amendment No. 1 dated as of March 26, 2002 (“Amendment No. 1”) and Amendment No. 2 dated as of August 30, 2004 (“Amendment No. 2”) (the Original Agreement, as so amended by Amendments No. 1 and 2, the “Development and Supply Agreement”); and
